1404367-02-7

Upstream product

• 348-54-9 2-Fluoroaniline 
• 349097-66-1 3-chloro-N-(2-fluoro-phenyl)-propionamide 
• 1464115-37-4 (9-fluoro-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)boronic acid 
• 142137-17-5 3-bromo-5-phenylpyridine 
• 1404367-55-0 7-bromo-9-fluoro-4,5-dihydro-1-methyl-[1,2,4]triazolo[4,3-a]quinoline 
• 1404367-54-9 6-bromo-8-fluoro-3,4-dihydroquinoline-2(1H)-thione 
• 1194459-25-0 6-bromo-8-fluoro-3,4-dihydro-1H-quinolin-2-one 
• 143268-79-5 8-fluoro-3,4-dihydro-1H-quinolin-2-one 

Relevant academic research and scientific papers

Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a ]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability

CYP11B2 inhibition is a promising treatment for diseases caused by excessive aldosterone. To improve the metabolic stability in human liver miscrosomes of previously reported CYP11B2 inhibitors, modifications were performed via a combination of ligand-and

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.